contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


finnish-private-clinic-group-orders-two-nexstim-nbs-6-systems

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Yep. I have strong confidence that this will still be a positive surprise in late winter. As long as the same trend continues until the end, that deals made by distributors in the Brainlab area are not announced. Brainlab has so many sellers and so many ready customers that it would be really strange if not a single deal were made.? Let’s imagine, say, a light 10 devices that weren’t announced, that’s about 3 million

It has also been stated in the interview that as distributors gradually withdraw, inquiries will subsequently be directed to Brainlab regarding the distributors. I don’t believe that inquiries would have ceased during the transition phase; rather, Brainlab has handled those nascent leads like a baton pass, smoothly bringing them to completion with X sales volumes thereafter.

Based on announcements and my calculations, 31 machines have been delivered or ordered this year. Correct me if I calculated wrong. Regarding these speculations about the announcement and sales of diagnostic devices, the last deal that I believe could fall into the Brainlab category was made on October 7th. The others are Nexstim’s own deals. I must say that I am slowly starting to interpret the CEO’s statements in the latest interview to mean that Brainlab’s deals are not being announced. I find it highly unlikely that Brainlab would make zero deals and Nexstim seven. However, Brainlab has been heavily exhibiting the device at trade shows, and the NBS6 device has certainly been anticipated on the market. @Mikko_Karvinen_Nexst, is it possible to clarify/confirm what you said in the interview, that for competitive reasons, Brainlab’s deals or Sinaptica’s machine numbers are only announced in reports?

My theory is as follows: Terveystalo has now purchased two devices to update the NBS 5 devices that came with Recuror to the latest generation of devices, as their own staff will be trained at these two Terveystalo locations. It makes sense to update the devices used for training to the same device version that will be ordered for other clinics in the future. Otherwise, those Recuror’s NBS 5 devices would still have had remaining lifespan. Recuror was founded in 2021 and the devices have a lifespan of 7 years.

It was not directly mentioned in the press release, but the only Finnish private operator that has had two old devices in use has been Recuror, which Terveystalo acquired last summer. So, Terveystalo will also continue with Nexstim devices, and now we await the expansion of treatment offerings to Terveystalo’s locations across Finland. There is undoubtedly demand among insurance and occupational health customers. Additionally, it is likely possible to alleviate the burden on the public sector through service vouchers.

Here is the announcement, gentlemen!                   nexstim.com              Nexstim - Press-release

I’ve been waiting for this, for when these multi-orders start coming! For crying out loud!

Nexstim

Press release, Helsinki, 16 December 2025 at 9 AM (EET) Finnish Private Clinic Group Orders Two Nexstim NBS 6 SystemsNexstim Plc ("Nexstim" or "Company") has received an order for two NBS 6 ...

Press release, Helsinki, 16 December 2025 at 9 AM (EET)&nbsp;Finnish Private Clinic Group Orders Two Nexstim NBS 6 SystemsNexstim Plc ("Nexstim" or "Company") has received an order for two NBS 6 therapy systems from a customer in Finland. The customer is a private healthcare provider that is replacing their current Nexstim therapy systems with new NBS 6 systems.In therapy, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain. The NBS 6 enables Nexstim’s unique E-field navigated TMS technology to be used more easily than ever before. Part of this new product generation is an easy-to-use, software-guided application and a modular product design that allows for system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests.&nbsp;Mikko Karvinen, CEO of Nexstim, comments: “We are happy to see our customers gain positive experiences with our products, and excited to continue the treatment journey with this Finnish private healthcare provider. Finland has always been an important home market for Nexstim, and we are proud of our strong customer base. This order demonstrates the growing confidence in our technology in therapy applications and reflects our shared commitment to improving patient care.”Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO+358 50 326 4101mikko.karvinen@nexstim.com&nbsp;About Nexstim PlcNexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.Nexstim shares are listed on Nasdaq First North Growth Market Finland.For more information, please visit <a href="http://www.nexstim.com">www.nexstim.com</a> <div> <hr> <div>Attachments</div> <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/nexstim/attachments/b4b647a6-b5c0-4049-9691-093de66d08d2/nexstim-plc-press-release-fin-order-16122025-final.pdf">Nexstim Plc_Press release_Fin order_16122025_FINAL.pdf</a></div> </div>